Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Item No. 24548

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
Neuropeptide FF (NPFF) is a peptide expressed in the brain and spinal cord that shares a precursor protein with neuropeptide AF.1 NPFF is expressed primarily in the posterior pituitary, hypothalamus, and medulla. It is an agonist at NPFF1 and NPFF2 receptors (Kis = 2.82 and 0.21 nM, respectively, for human recombinant receptors) that inhibits forskolin-induced cAMP production in CHO cells (EC50s = 236 and 2.3 nM, respectively).2 NPFF activates parvocellular neurons in the paraventricular nucleus (PVN) of the hypothalamus to stimulate oxytocin release from their projections in the brain stem, thereby regulating baroreflex control of heart rate.3 However, it inhibits magnocellular PVN neurons by enhancing GABAergic input. It is also found in plasma and exogenous administration briefly increases mean arterial pressure (MAP) by 40 mm Hg in rats, an effect that is only partially blocked by the norepinephrine competitor guanethidine (Item No. 16217) and the α1-adrenergic receptor antagonist prazosin (Item No. 15023).4 NPFF has anti-opioid effects in rodent models, inhibiting morphine-induced analgesia and inducing abstinence in morphine-tolerant rats.1,5 It also inhibits acquisition of conditioned place preference to cocaine in rats when administered at doses of 10 and 20 nmol.6
WARNING This product is not for human or veterinary use.
1. Neuropeptide FF, a mammalian neuropeptide with multiple functions. Prog. Neurobiol. 48(4-5), 461-487 (1996).
2. Pharmacological characterization of human NPFF1 and NPFF2 receptors expressed in CHO cells by using NPY Y1 receptor antagonists. Eur. J. Pharmacol. 451(3), 245-256 (2002).
3. Role of neuropeptide FF in central cardiovascular and neuroendocrine regulation. Front. Endocrinol. (Lausanne) 4:8, (2013).
4. Elevation of arterial pressure in rats by two new vertebrate peptides FLFQPQRF-
5. Identification and characterization of novel mammalian neuropeptide FF-
6. Neuropeptide FF (NPFF) reduces the expression of cocaine-